Survival Benfit Fo Transarterial Chemoembolization Combined With Endovascular Implant Iodin-125 Seed Versus Transarterial Chemoembolization Combined With External Radiotherapy For The Inoperable Patient Of The Hepatocellular Carcinoma With Portal Vein Tum

Objective: To compare the efficacy and safety of transarterial chemoembolization combined with endovascular Implant Iodin-125 seed and transarterial chemoembolization combined with external radiotherapy for the inoperable patient of hepatic carcinoma with portal vein tumor thrombus.Methods : This study retrospectively analyzed 70 cases of unable to surgical resectio n of hepatic carcinoma with portal vein tumor thrombus in patients with clinical data.The data can be divided into two groups: a group(35 cases)patients accepted transarterial chemoembolization combined with endovascular Implant Iodin-125 seed,another group(35 cases)patients accepted transarterial chemoembolization combined with external radiotherapy.Comparing two groups of patients' survival,to determine whether two different treatment for the patient survival,a secondary end point was the tumor response and adverse reactions.At the same time,univariate and multi-variate survival analysis were performed.Results :The overall survival in TACE combined with iodine 125 seed group better than than in TACE combined with external radiotherapy group(15 month vs 13 month),but it was not significant(P=0.570).The adverse events in the TACE combined with iodine 125 seed group is less significantly than in the TACE combined with external radiotherapy group(P<0.001).The first group can improve the life quality of patiencts.Conclusion : The Survival benfit in TACE combined with iodine 125 seed group was not significantly better than than in TACE combined with external radiotherapy group,but the adverse events of the TACE combined with iodine 125 seed gtoup was significantly less.It improves the quality of life after treatment.